EP 4400175 A3 20240925 - METHODS OF TREATING RHEUMATOID ARTHRITIS USING RNA-GUIDED GENOME EDITING OF HLA GENE
Title (en)
METHODS OF TREATING RHEUMATOID ARTHRITIS USING RNA-GUIDED GENOME EDITING OF HLA GENE
Title (de)
VERFAHREN ZUR BEHANDLUNG VON RHEUMATOIDER ARTHRITIS MIT RNA-GEFÜHRTER GENOMBEARBEITUNG DES HLA-GENS
Title (fr)
MÉTHODES DE TRAITEMENT DE LA POLYARTHRITE RHUMATOÏDE PAR ÉDITION GÉNOMIQUE GUIDÉE PAR L'ARN D'UN GÈNE HLA
Publication
Application
Priority
- US 201762491487 P 20170428
- US 2018029302 W 20180425
- EP 18791113 A 20180425
Abstract (en)
Methods of preventing or treating rheumatoid arthritis (RA) in a subject by introducing the DRB1*04:01<sup>K71E</sup> mutation that is resistant to RA. The resistant allele is introduced into the subject having or at risk of developing RA, using a HLA CRISPR/Cas9 vector that targets codon 71 in the HLA allele DRB1*04:01, introducing a single A to G point mutation in codon 71 by homology directed repair to alter the lysine at position 71 of the expressed protein to glutamic acid. This modified allele is affected in the subject's hematopoietic stem cells, which are then expanded and transplanted back into the patient. This microgene therapy confers RA-resistance via an autologous transplant. The invention includes isolated nucleic acids, vectors, recombinant viruses, cells, and pharmaceutical compositions to modify the HLA DRB1*04:01 allele.
IPC 8 full level
C12N 15/113 (2010.01); A61K 35/14 (2015.01); A61K 48/00 (2006.01); A61P 19/02 (2006.01); A61P 37/00 (2006.01); C12N 15/861 (2006.01); C12N 15/867 (2006.01); C12N 15/90 (2006.01); A01K 67/027 (2024.01)
CPC (source: EP US)
A01K 67/0275 (2013.01 - EP US); A61K 35/28 (2013.01 - EP US); A61P 19/02 (2018.01 - EP); A61P 37/00 (2018.01 - EP); C12N 5/0647 (2013.01 - US); C12N 9/22 (2013.01 - US); C12N 15/11 (2013.01 - US); C12N 15/1138 (2013.01 - EP); C12N 15/85 (2013.01 - US); C12N 15/90 (2013.01 - EP); A01K 2217/05 (2013.01 - EP US); A01K 2227/105 (2013.01 - EP US); A01K 2267/0325 (2013.01 - EP US); A61K 48/00 (2013.01 - EP US); A61K 48/005 (2013.01 - EP); C12N 2310/20 (2017.05 - EP US); C12N 2740/15042 (2013.01 - US); C12N 2740/16043 (2013.01 - EP); C12N 2750/14142 (2013.01 - US); C12N 2800/80 (2013.01 - US)
Citation (search report)
- [XAY] WO 2016201047 A1 20161215 - EDITAS MEDICINE INC [US]
- [X] WO 2016021972 A1 20160211 - COLLEGE MEDICINE POCHON CHA UNIV IND ACAD COOP FOU [KR], et al
- [YD] ANDERSON K M ET AL: "A Molecular Analysis of the Shared Epitope Hypothesis: Binding of Arthritogenic Peptides to DRB1*04 Alleles", ARTHRITIS & RHEUMATOLOGY, vol. 68, no. 7, July 2016 (2016-07-01), pages 1627 - 1636, XP055774031, ISSN: 2326-5191, DOI: 10.1002/art.39636
- [AD] ROARK C L ET AL: "Arthritogenic peptide binding to DRB1*01 alleles correlates with susceptibility to rheumatoid arthritis", JOURNAL OF AUTOIMMUNITY, vol. 72, 30 April 2016 (2016-04-30), pages 25 - 32, XP029651657, ISSN: 0896-8411, DOI: 10.1016/J.JAUT.2016.04.006
- [T] ROARK C ET AL: "Progress towards gene editing of HLA-DRB1*04:01 by CRISPR/Cas9", HUMAN IMMUNOLOGY, vol. 79, no. Suppl., P162, 31 August 2018 (2018-08-31), ican 44th Annual Meeting of the American Society for Histocompatibility and Immunogenetics; Baltimore, MD, USA; 1-5 October 2018, pages 186, XP085459804, ISSN: 0198-8859, DOI: 10.1016/J.HUMIMM.2018.07.219
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2018200635 A1 20181101; AU 2018258061 A1 20191128; CA 3061614 A1 20181101; DK 3615674 T3 20240617; EP 3615674 A1 20200304; EP 3615674 A4 20210324; EP 3615674 B1 20240313; EP 4400175 A2 20240717; EP 4400175 A3 20240925; ES 2981611 T3 20241009; FI 3615674 T3 20240618; JP 2020517289 A 20200618; JP 2024075603 A 20240604; JP 7457302 B2 20240328; LT 3615674 T 20240925; US 11932867 B2 20240319; US 2020199616 A1 20200625; US 2024327862 A1 20241003
DOCDB simple family (application)
US 2018029302 W 20180425; AU 2018258061 A 20180425; CA 3061614 A 20180425; DK 18791113 T 20180425; EP 18791113 A 20180425; EP 24162513 A 20180425; ES 18791113 T 20180425; FI 18791113 T 20180425; JP 2019558446 A 20180425; JP 2024033480 A 20240306; LT US2018029302 T 20180425; US 201816609175 A 20180425; US 202418605149 A 20240314